Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective foliow-up

Journal of Acquired Immune Deficiency Syndromes

Volumn 6, Issue 9, 1993, Pages 1049-1056

  Metzger, David S ^a   Woody, George E ^a   McLellan, A Thomas ^a   O'Brien, Charles P ^a   Druley, Patrick ^a   Navaline, Helen ^a   DePhilippis, Dominick ^a   Stolley, Paul ^b   Abrutyn, Elias ^c  

^a University of Pennsylvania/VA Center for Studies of Addiction ^*  (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Human immunodeficiency virus; Incidence; Intravenous drug users; Methadone treatment; Prevalence; Risk interventions

Indexed keywords

METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; RISK FACTOR; SEROCONVERSION; SERODIAGNOSIS; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH BEHAVIOR; HIV INFECTIONS; HUMAN; INCIDENCE; MALE; METHADONE; PHILADELPHIA; PREVALENCE; PROSPECTIVE STUDIES; SEX BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027237484     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hahn RA, Onorato IM, Jones ST, et al. Prevalence of HIV infection among intravenous drug users in the United States. JAMA 1989; 269:2677-84.
2. Centers for Disease Control. Update: acquired immunodeficiency syndrome associated with intravenous drug use—United States, 1988. MMWR 1989; 38:165-70.
3. Centers for Disease Control CDC. The HIV/AIDS epidemic: the first 10 years. MMWR 1991; 40:357-69.
4. Lee HH, Weiss SH, Brown LS, et al. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle Atlantic and central regions of the USA. J Infect Dis 1990; 162:347-62.
5. Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261:561-5.
6. Koblin BA, McCusker J, Lewis BF, et al. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol 1990; 132:837-45.
7. Nelson KE, Vlahov D, Cohn S, Lindsay A, Solomon L, Anthony JC. Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA 1991; 266(16):2259-61.
8. Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA 1989; 261:1008-12.
9. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989; 321:874-9.
10. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214-26.
11. Hubbard RL, Marsden ME, Cavanaugh E, et al. Role of drug abuse treatment in limiting the spread of AIDS. Rev Infect Dis 1988; 10:377-84.
12. Gerstein DR, Harwood HJ, eds. Treating drug problems: a study of the evolution, effectiveness, and financing of public and private drug treatment systems, vol. 1. Washington, D.C.: Institute of Medicine, 1990.
13. Abdul-Quader AS, Friedman SR, DesJarlais D, et al. Methadone maintenance and behavior by intravenous drug users that can transmit HIV. Contemp Drug Prob 1987; 11:425-34.
14. Novick DM, Farci P, Croxson TS, et al. Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis 1988; 158:795-803.
15. McLellan AT, Luborsky L, O’ Brien CP, et al. An improved evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis 1980; 168:26-33.
16. Centers for Disease Control. CDC. Risk behaviors for HIV transmission among intravenous drug users not in treatment: United States 1987-1989. MMWR 1990; 39:273-6.
17. Metzger DS, Woody GE, McLellan AT, et al. The impact of HIV testing on risk for AIDS behaviors. In: Harris L., ed. Problems of drug dependance: Proceedings of the 53rd Annual Scientific Meeting. Rockville MD: National Institute on Drug Abuse. NIDA Research Monograph No. 119, 1992; 297-8.
18. Des Jarlais DC, Friedman SR, Marmor M, et al. Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. AIDS 1987; 1:105-11.
19. Anthony JC, Vlahov D, Nelson KE, Cohn S, Astemborski J, Solomon L. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol 1991; 134(10):1175-88.
20. Novick DM, Ochshorn M, Violette G, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989; 250:2606-10.
21. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.
22. van Ameijden EJC, van den Hoek JAR, van Hastrect HJA, Coutinho RA. The harm reduction approach and risk reduction for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. Am J Epidemiol 1992; 136:236-43.
23. Zangerle R, Fuchs D, Rossler H, et al. Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J Acquir Immun Defic Syndr 1992; 5:865-71.
24. Metzger DS, Woody GE, DePhilippis D, et al. Risk factors for needle sharing among methadone treated patients. Am J Psychiatry 1991; 148:636-40.
25. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. In: Hartsock P, Genser SG, eds. Longitudinal studies of HIV infection among intravenous drug users: methodological issues in natural history research. Rockville, MD: National Institute on Drug Abuse, NIDA Research Monograph No. 109. 1991; 735-53.
26. Booth R, Weibel WW. Effectiveness of reducing needle related risks for HIV through indigenous outreach to injection drug users. Am J Addicts 1992; 1:277-87.
27. Iguchi MY. Human immunodeficiency virus seroprevalence and correlates of risk in Newark and Jersey City. In: Epidemiologic trends in drug abuse: community epidemiologic work group, June 1992. DHHS Publication No. (ADM) 92-1958. 1992; 484-93.
28. Liebman J, Thomas C. Development of a sampling strategy to monitor trends in human immunodeficiency virus risk behavior in out-of-treatment drug users. In: Epidemiologic trends in drug abuse: community epidemiologic work group, June 1992. DHHS Publication No. (ADM) 92-1958. 1992; 494-502.
29. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-5.